FDA’s final guidance on disclosure of potential financial conflicts of interest by clinical investigators offers sponsors some more details on how to fulfill the agency’s requests, but the document retains two serious consequences related to the disclosure process – FDA can refuse to file applications without proper disclosures, and the data itself could be released when the agency approves the drug.
The agency said the final guidance
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?